Mela jumps as panel backs MelaFind

Mela Sciences Inc. (NASDAQ:MELA) spiked $2.45 (97%) to $4.98 on Friday after an FDA advisory committee voted 8-7, with one abstention, on Thursday that the benefits of melanoma diagnostic candidate MelaFind outweigh its risks. The General and Plastic Surgery Devices Panel also voted 10-6 that the safety data for MelaFind were adequate and voted 8-2, with two abstentions, that the data showed sufficient efficacy. Mela said FDA has not provided a decision date for the PMA for MelaFind, which is under review to assist in evaluating pigmented skin lesions with characteristics of melanoma prior to biopsy. ...